60 Racial Disparities in Hospitalization Outcomes Among Women With Metastatic Breast Cancer in the United States by Palliative Care Utilization

Publication
Article
Miami Breast Cancer Conference® Abstracts Supplement41st Annual Miami Breast Cancer Conference® - Abstracts
Volume 38
Issue 4
Pages: 74-75

Background

While studies have reported that members of racial and minority populations hospitalized with metastatic breast cancer (MBC) have lower palliative care use than non-Hispanic White women, disparities in hospital-associated outcomes among inpatients have not been explored in this population. We examined the racial disparities in hospitalization outcomes among adult women with a diagnosis of MBC, stratified by receipt of palliative care.

Methods

Retrospective cohort analyses were conducted using the Agency for Healthcare Research and Quality (AHRQ)–sponsored Healthcare Cost and Utilization Project, National Inpatient Sample (HCUP–NIS) database from 2016 to 2020. Multivariable logistic and linear regression models were used to examine the association between race/ethnicity and in-hospital mortality, length of stay, and total hospital charges. Multinomial logistic regression models were used to evaluate the association between race/ethnicity and discharge disposition. Stratified analyses were conducted by palliative care use. Results were reported as adjusted odds ratios (AOR).

Results

Racial Disparities in Hospitalization Outcomes Among Women With Metastatic Breast Cancer by Palliative Care Receipt

Racial Disparities in Hospitalization Outcomes Among Women With Metastatic Breast Cancer by Palliative Care Receipt

Racial Disparities in Hospitalization Outcomes Among Women With Metastatic Breast Cancer by Palliative Care Receipt (cont.)

Racial Disparities in Hospitalization Outcomes Among Women With Metastatic Breast Cancer by Palliative Care Receipt (cont.)

In the adjusted analyses, Black (AOR, 1.25; 95% CI, 1.16-1.34), Hispanic (AOR, 1.12; 95% CI, 1.01-1.23), and other (AOR, 1.26; 95% CI, 1.12-1.40) MBC patients had higher in-hospital mortality compared to the White patients. After stratifying by palliative care use, Black women who received palliative care had similar odds (AOR, 1.08; 95% CI, 0.97-1.20) of in-hospital mortality while those without palliative care use had 46% higher odds (95% CI, 1.30-1.64) of mortality when compared to White women. Black women were more likely (AOR, 1.18; 95% CI, 1.13-1.23) to have a length of stay greater than 5 days compared to 5 days or less relative to White women. Furthermore, Black, Hispanic, and other women had higher total hospital charges when compared with patients who are White. While women who were Black had similar odds (AOR, 0.98; 95% CI, 0.92-1.04) of being discharged to a short-term/skilled nursing facility vs routine discharge compared with women who were White, women who were Black who received palliative care had 19% (95% CI, 0.70-0.95) lower odds of being discharged to a facility. Hispanic and other MBC patients were less likely to be discharged to a facility relative to routine discharge when compared with women who were White.

Conclusions

Despite the improvement in palliative care use over the years, members of racial minority populations continue to have poorer outcomes. However, patients who are Black with MBC who received palliative care had similar in-hospital mortality and were less likely to be discharged to a facility when compared with their White counterparts. Our findings emphasize the importance of palliative care use among MBC patients and highlight the need to continue to raise awareness of its benefits, especially in minority populations. Further studies are needed to explore ways to narrow the gap in existing disparities and to test these interventions on care metrics and patient outcomes.

Articles in this issue

1 Centrally Located Breast Cancer Is More Aggressive in Bahraini Patients
1 Centrally Located Breast Cancer Is More Aggressive in Bahraini Patients
2 Is Laterality in Breast Cancer Still Worth Studying? Local Experience in Bahrain
2 Is Laterality in Breast Cancer Still Worth Studying? Local Experience in Bahrain
3 Gender Disparities in the  National Institutes of Health  Funding for Breast Cancer
3 Gender Disparities in the National Institutes of Health Funding for Breast Cancer
4 Bacopaside: Exploring Its Potential in Addressing Chemoresistance and Modulating Doxorubicin Accumulation in Triple-Negative Breast Cancer Cells
4 Bacopaside: Exploring Its Potential in Addressing Chemoresistance and Modulating Doxorubicin Accumulation in Triple-Negative Breast Cancer Cells
5 Predictors of Axillary Complete Pathologic Response in Hormone Receptor–Positive, HER2-Negative, Clinically Node-Positive Breast Cancer
5 Predictors of Axillary Complete Pathologic Response in Hormone Receptor–Positive, HER2-Negative, Clinically Node-Positive Breast Cancer
6 Treatment Outcomes of the KEYNOTE-522 Regimen in an Ethnically Diverse Patient Population
6 Treatment Outcomes of the KEYNOTE-522 Regimen in an Ethnically Diverse Patient Population
7 Real-World Efficacy and Adverse Events of Neoadjuvant Immunotherapy in Early-Stage Triple-Negative Breast Cancer Patients: A Multicenter Experience
7 Real-World Efficacy and Adverse Events of Neoadjuvant Immunotherapy in Early-Stage Triple-Negative Breast Cancer Patients: A Multicenter Experience
8 Using a Liquid Biopsy Mediated Approach for Determination of HER2 Amplification Status in Patient Samples
8 Using a Liquid Biopsy Mediated Approach for Determination of HER2 Amplification Status in Patient Samples
9 Elacestrant (ELA) vs Standard-of-Care (SOC) in ER+/HER2–Advanced (adv) or Metastatic Breast Cancer (mBC) with ESR1 Mutation (ESR1-mut): Key Biomarkers and Clinical Subgroup Analyses From the Phase 3 EMERALD Trial
9 Elacestrant (ELA) vs Standard-of-Care (SOC) in ER+/HER2–Advanced (adv) or Metastatic Breast Cancer (mBC) with ESR1 Mutation (ESR1-mut): Key Biomarkers and Clinical Subgroup Analyses From the Phase 3 EMERALD Trial
10 Real-World Effectiveness of Palbociclib (PAL) Plus Aromatase Inhibitors (AI) in Patients With Metastatic Breast Cancer (MBC) and Cardiovascular Diseases (CVD)
10 Real-World Effectiveness of Palbociclib (PAL) Plus Aromatase Inhibitors (AI) in Patients With Metastatic Breast Cancer (MBC) and Cardiovascular Diseases (CVD)
11 Phase 3 Study of Neoadjuvant Pembrolizumab or Placebo Plus Chemotherapy, Followed by Adjuvant Pembrolizumab or Placebo Plus Endocrine Therapy for Early-Stage High-Risk ER+/HER2– Breast Cancer: KEYNOTE-756
11 Phase 3 Study of Neoadjuvant Pembrolizumab or Placebo Plus Chemotherapy, Followed by Adjuvant Pembrolizumab or Placebo Plus Endocrine Therapy for Early-Stage High-Risk ER+/HER2– Breast Cancer: KEYNOTE-756
12 EMERALD Trial Analysis of Patient-Reported Outcomes (PROs) in Patients (pts) With ER+/HER2- Advanced or Metastatic Breast  Cancer (mBC) Comparing Oral Elacestrant vs Standard-of-Care (SoC) Endocrine Therapy
12 EMERALD Trial Analysis of Patient-Reported Outcomes (PROs) in Patients (pts) With ER+/HER2- Advanced or Metastatic Breast Cancer (mBC) Comparing Oral Elacestrant vs Standard-of-Care (SoC) Endocrine Therapy
13 The Cause and Eradication of Breast Cancer
13 The Cause and Eradication of Breast Cancer
14 Outcomes With First-Line (1L) Ribociclib (RIB) + Endocrine Therapy (ET) vs Physician’s Choice Combination Chemotherapy (combo CT) by Age in Pre/Perimenopausal Patients (pts) With Aggressive HR+/HER2– Advanced Breast Cancer (ABC): A Subgroup Analysis of the RIGHT Choice Trial
14 Outcomes With First-Line (1L) Ribociclib (RIB) + Endocrine Therapy (ET) vs Physician’s Choice Combination Chemotherapy (combo CT) by Age in Pre/Perimenopausal Patients (pts) With Aggressive HR+/HER2– Advanced Breast Cancer (ABC): A Subgroup Analysis of the RIGHT Choice Trial
15 Concurrent Use of Abemaciclib and Radiation Therapy (RT) Among Patients With HR+, HER2– Metastatic Breast Cancer (MBC): Real-World Utilization and Safety
15 Concurrent Use of Abemaciclib and Radiation Therapy (RT) Among Patients With HR+, HER2– Metastatic Breast Cancer (MBC): Real-World Utilization and Safety
Recent Videos
Updated results from the 1b/2 ELEVATE study elucidate synergizing effects observed with elacestrant plus targeted therapies in ER+/HER2– breast cancer.
Patients with ESR1+, ER+/HER2– breast cancer resistant to chemotherapy may benefit from combination therapy with elacestrant.
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
Study findings reveal that patients with breast cancer reported overall improvement in their experience when receiving reflexology plus radiotherapy.
Patients undergoing radiotherapy for breast cancer were offered 15-minute nurse-led reflexology sessions to increase energy and reduce stress and pain.
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Ultra-hypofractionated radiation in those 65 years or older with early breast cancer yielded no ipsilateral recurrence after a 10-month follow-up.
The unclear role of hypofractionated radiation in older patients with early breast cancer in prior trials incentivized research for this group.
Related Content